Emerging organoid models: leaping forward in cancer research
Open accessThe DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Cancer heterogeneity is regarded as the main reason for the failure of conventional cancer therapy. The ability to reconstruct intra- and interpatient heterogeneity in cancer models is crucial for understanding cancer biology as well as for developing personalized anti-cancer therapy. Cancer organoids represent an emerging approach for creating patient-derived in vitro cancer models that closely recapitulate the pathophysiological features of natural tumorigenesis and metastasis. Meanwhile, cancer organoids have recently been utilized in the discovery of personalized anti-cancer therapy and prognostic biomarkers. Further, the synergistic combination of cancer organoids with organ-on-a-chip and 3D bioprinting presents a new avenue in the development of more sophisticated and optimized model systems to recapitulate complex cancer-stroma or multiorgan metastasis. Here, we summarize the recent advances in cancer organoids from a perspective of the in vitro emulation of natural cancer evolution and the applications in personalized cancer theranostics. We also discuss the challenges and trends in reconstructing more comprehensive cancer models for basic and clinical cancer research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tumor organoids can be generated from patient/mouse-derived tumor cells or by engineering induced pluripotent stem cells (iPSCs) followed by gene editing to transform a normal organoid into a cancer organoid [33,59].”
From 3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions (2021) · cites this paper as [59]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, organoids are more advantageous due to the ease of culturing and closer resemblance to the TME, thus being more pathophysiologically relevant as compared to the patient‐derived tumor xenograft (PDX) model and other tumor‐bearing animal models, which are more tedious and expensive to maintain [384, 395].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [384]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Moreover, organoids can be ef fi ciently cultured with a patient ' s own cells, and are thus a better alternative to expensive and labor-intensive patient-derived tumor xenografts [59], and are also more cost-effective and physiologically relevant than animal models.”
From 3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions (2021) · cites this paper as [59]
The cited source says what the claim attributes to it.
In the citing paper
“3D bioprinting can also be used with organoids to form sophisticated organoid culture systems [59].”
From 3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions (2021) · cites this paper as [59]
The cited source says what the claim attributes to it.
In the citing paper
“By contrast, organoid models usually only contain progenitor cells of epithelial origin, hence there is a lack of an immune-competent microenvironment and stromal components in tumor organoid models [59].”
From 3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions (2021) · cites this paper as [59]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Clonal heterogeneity and tumor evolution: past, present, and the future
McGranahan, N., & Swanton, C. (2017) · Cell · doi:10.1016/j.cell.2017.01.018 · Cited by 2,840 · cited 1×
“The tumor heterogeneity results in significant differences in the tumor growth rate, invasion ability, drug sensitivity, and prognosis among individual patients [2].”
BackgroundClinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536 · cited 1×
“Moreover, even FDA-approved anticarcinogens display heterogeneous therapeutic responses and prognosis across individual patients [57].”
BackgroundProspective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.053 · Cited by 2,408 · cited 3×
“CRC 22 cancer organoids from 27 tumor samples ~90% Surgically resected Support Royal Netherlands Academy of Arts and Sciences, Holland [9]”
BackgroundOrganoid models of human and mouse ductal pancreatic cancer
Boj, S. F., Hwang, C.-I., Baker, L. A., Chio, I. I. C., Engle, D. D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M. S., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.021 · Cited by 2,150 · cited 2×
“Prostate cancer organoids Patient, Mouse Organoid culture and xenotransplantation Show the role of nucleoporins in the progression of pancreatic cancer [29]”
BackgroundPatient-derived organoids model treatment response of metastatic gastrointestinal cancers
Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018) · Science · doi:10.1126/science.aao2774 · Cited by 2,096 · cited 2×
“Cancer organoids derived from patients’ biopsies displayed the 100% sensitivity, 93% specificity, 88% positive predictive value, and 100% negative predictive value, compared to the drug responses in the corresponding patients [62].”
BackgroundResultA living biobank of breast cancer organoids captures disease heterogeneity
Sachs, N., de Ligt, J., Kopper, O., Gogola, E., Bounova, G., Weeber, F., Balgobind, A. V., Wind, K., Gracanin, A., Begthel, H., et al. (2018) · Cell · doi:10.1016/j.cell.2017.11.010 · Cited by 1,973 · cited 4×
“By comparing the therapeutic responses of anticarcinogen in the BC organoids and the corresponding patients, they found that the sensitivity to tamoxifen in the BC organoids was closely correlated with that in the original patients with metastatic BC [10].”
BackgroundResultInfluentialPatient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
Hidalgo, M., Amant, F., Biankin, A. V., Budinská, E., Byrne, A. T., Caldas, C., Clarke, R. B., de Jong, S., Jonkers, J., Mælandsmo, G. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0001 · Cited by 1,742
Organoid Cultures Derived from Patients with Advanced Prostate Cancer
Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., Dowling, C., Wanjala, J. N., Undvall, E. A., Arora, V. K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.016 · Cited by 1,559 · cited 3×
“In the repository, cancer organoids can be passaged and cryopreserved, just like immortal cell lines (Table 3) [30].”
Background
Research works printed but not linked: 1
- Society AC. Global Cancer Facts & Figures 3rd Edition. Am Cancer Soc. 2015;800:1–64.
Cited by
Hofer, M., & Lutolf, M. P. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00279-y · Cited by 1,184
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773
“However, organoids commonly contained only epithelial cells and lack fibroblasts and types of other cells, such as immune and endothelial cells.(77) To overcome these limitations of organoids, a multilayer bladder called an “assembloids” has been created by reconstituting tissue stem cells with stromal components repr…”
Background3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions
Rodrigues, J., Heinrich, M. A., Teixeira, L. M., & Prakash, J. (2021) · Trends in Cancer · doi:10.1016/j.trecan.2020.10.009 · Cited by 405
“Moreover, organoids can be efficiently cultured with a patient’s own cells, and are thus a better alternative to expensive and labor-intensive patient-derived tumor xenografts [59], and are also more cost-effective and physiologically relevant than animal models.”
BackgroundInfluentialTumor microenvironment: barrier or opportunity towards effective cancer therapy
Tiwari, A., Trivedi, R., & Lin, S.-Y. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00866-3 · Cited by 377
“These tumor model systems have removed the bottleneck of extrapolation of results from animal and patientderived xenografts (PDX) models [210, 211].”
BackgroundTumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Metadata
- Authors
- Fan, H., Demirci, U., & Chen, P.
- Affiliations
- Stanford Medicine (US)
- Wuhan University (CN)
- Corresponding author
- Demirci, Utkan
- Chen, Pu
- Venue
- Journal of Hematology & Oncology
- Published
- 2019-12
- Volume
- 12
- Issue
- 1
- Pages
- 142-142
- ISSN
- 1756-8722 (ISSN-L)
- PMC
- PMC6936115
- OpenAlex
- W2997819890
- Cited by
- 199
- References
- 71
- Citations by year
- 2026: 10 · 2025: 23 · 2024: 27 · 2023: 17 · 2022: 40 · 2021: 55 · 2020: 26
- FWCI
- 2.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 28 d)
- Locations
- Journal of Hematology & Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Key Research and Development Program of China (2018YFA0109000)
- Applied Foundational Research Program of Wuhan Municipal Science and Technology Bureau (2018010401011296)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- tumor organoids, patient-derived tumor models, tumor heterogeneity, precision oncology, organ-on-a-chip, 3D bioprinting, metastasis, tumor microenvironment, prognostic factors, cancer theranostics, in vitro tumor model
- MeSH terms
- Animals, Drug Evaluation, Preclinical, Humans, Models, Biological, Neoplasms, Organoids, Tissue Engineering, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging organoid models: leaping forward in cancer research. https://app.cochat.ai/papers/10.1186/s13045-019-0832-4
- The paper
- Fan, H., Demirci, U., & Chen, P. (2019). Emerging organoid models: leaping forward in cancer research. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-019-0832-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.